Treatment-emergent adverse events ( TEAEs ) were assessed using spontaneous patient/caregiver reporting and open-ended questioning ; clinical laboratory testing ( hematology , biochemistry , and urinalysis panels analyzed by a central laboratory ) ; 12-lead ECG ; and physical and neurologic examinations , including vital sign measurements .
